Piper Sandler analyst Matt O’Brien raised the firm’s price target on Globus Medical (GMED) to $115 from $90 and keeps an Overweight rating on the shares. The firm notes the company preannounced Q4 revenue of $823.2M, which comes in well above the Street’s $778.5M estimate. While the company did not specifically break out Enabling Technology revenue, it did disclose “best quarterly revenue to date” which is a clear positive and, although they are not completely out of the woods yet, signals that things are starting to pick back up again, Piper argues.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical: Strong Execution and Upside Revisions Balanced by Full Valuation Support Hold Rating
- Globus Medical: Strong Fundamentals and Outperformance Largely Priced In, Justifying a Hold Rating
- Closing Bell Movers: Defense stocks surge on Trump military budget comments
- Globus Medical sees FY25 revenue $2.936B, consensus $2.89B
- Globus Medical sees FY26 adjusted EPS $4.30-$4.40, consensus $4.12